Goldman Sachs has upgraded Ionis Pharmaceuticals Inc (IONS) from Sell to Neutral as of September 25, 2025. This shift in rating suggests a more favorable outlook on the company’s prospects, potentially indicating improved fundamentals or confidence in its strategic direction.
Headquartered in Carlsbad, California, Ionis Pharmaceuticals specializes in the development and commercialization of human therapeutic drugs utilizing antisense technology. The company currently employs 1,069 full-time staff and has a market cap of $11.7 billion. Its portfolio includes several marketed medicines such as TRYNGOLZA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA, which target various serious health conditions.
Despite an EPS of -1.71 in the trailing twelve months, Ionis has demonstrated surprising performance in recent quarters, exceeding earnings expectations consistently. For instance, in Q3 2025, the company reported an EPS of -0.80, outperforming estimates by 36.4%. Analysts project upcoming earnings on July 28, 2026, with an estimated EPS of -0.74 and revenue of $214.6 million.
Such decisions reflect the dynamic nature of analyst ratings, which can change as new information becomes available. Investors are reminded that while analyst assessments provide insights, they should be considered alongside various factors, including company fundamentals and market conditions.